低风险人群普筛常染色体显性单基因病cfDNA的成本效果分析
普遍筛查约减少2979例受累活产,在检测成本不超过1094美元时具成本节约性,并增加10477个母亲QALY。结论为模型预测,需前瞻性实施研究验证。
要点
- 普遍cfDNA单基因病筛查在模型中可减少受累活产并具成本节约性。
- 检测成本超过1094美元时成本节约性不再成立。
- 普遍筛查额外增加10477个母亲QALY。
核心结论
- 在本模型及指定假设下,普遍cfDNA单基因病筛查相较超声指征筛查具成本节约性并增加母亲QALY。
- 上述为模型预测而非观察结局,常规纳入产前保健前需前瞻性实施研究。
研究设计与样本
- 使用TreeAge软件构建决策分析模型,比较普遍cfDNA单基因病筛查与仅在异常时提供该检测的策略。
- 成本效果阈值设为每QALY 100000美元。
主要发现
- 普遍cfDNA单基因病筛查策略约减少2979例受累活产。
- 鉴于受累活产相关高额照护成本,模型预测在检测成本不超过1094美元时普遍筛查具成本节约性。
- 普遍筛查策略预测额外增加10477个母亲QALY。
关键数值与推荐
- 成本效果阈值为每QALY 100000美元。
- 检测成本超过1094美元时,普遍筛查不再具成本节约性。
临床怎么用
- 可为低风险产科人群普遍cfDNA单基因病筛查的成本效果评估提供模型依据。
- 检测定价不超过1094美元时,模型支持普遍筛查具成本节约性。
- 临床常规开展前应等待前瞻性实施研究结果。
局限性
- 结果为模型预测而非观察结局。
- 结论依赖模型指定假设,需前瞻性实施研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The use of cell free fetal DNA has expanded to include autosomal dominant single gene conditions (cfDNA-SGD). Our aim is to estimate the cost-effectiveness of a cfDNA-SGD panel in a general obstetric population as compared to offering this test only in the setting of anomalies. METHODS: Using TreeAge software, we created a decision-analytic model to compare outcomes of the universal cfDNA-SGD. The screening conditions included in the current panel were separated into tiers (1, 2, 3) based on severity and life expectancy of the conditions. Outcomes included miscarriage after diagnostic procedure, termination, neonatal death, and the outcome of affected livebirth. The cost-effectiveness threshold was set at $100,000 per QALY. RESULTS: When applied to a theoretical cohort of 3.7 million individuals, the strategy of universal cfDNA-SGD resulted in approximately 2979 fewer affected livebirths. Given the high costs of care associated with an affected liveborn, universal cfDNA-SGD was projected to be cost-saving in this model until the test cost exceeded $1094. The universal cfDNA-SGD strategy was also projected to yield an additional 10,477 maternal QALYs. CONCLUSION: In this model, and under the assumptions specified, universal cfDNA-SGD was projected to be cost-saving and to yield additional maternal QALYs relative to ultrasound-indicated cfDNA-SGD. These are model-based projections rather than observed outcomes; prospective implementation studies will be needed before any conclusion can be drawn about routine integration into prenatal care.
引用
- Bunnell ME, Packer CH, Adams S, et al. Universal Prenatal cfDNA-Single Gene Disorder Screening for Autosomal Dominant Conditions in a Low-Risk Cohort: A Cost-Effectiveness Analysis. Prenat Diagn. 2026. PMID: 42833186. doi:10.1002/pd.70269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。